BIOASTER is proud to be part of ERA4TB (European Regimen Accelerator for #Tuberculosis) project, a public-private initiative devoted to accelerating the development of new treatment regimens for tuberculosis. The ERA4TB...
BIOASTER, today announced a collaboration with QIAGEN for the development of a molecular diagnostic assay running on the QIAGEN’s QIAstat-Dx platform. The primary objective of the collaboration is to expand...
INCATE (the INCubator for Antibacterial Therapies in Europe) and BIOASTER, the French Microbiology Technology Research Institute, have announced this week the beginning of a new partnership that aims to improve...
We are pleased to share with you the press release on our joint “S.O.L.V.E. AMR” initiative with Cynbiose, Pharmalex and ICTA. S.O.L.V.E AMR (Solutions for Overcoming and Leveraging Versatile Efforts...
Onchocerciasis, also known as river blindness, stands as the second leading cause of infectious blindness worldwide. According to estimates by the World Health Organization (WHO), approximately 25 million...
BIOASTER est fier d’être partenaire pour les 1ères rencontres FRANCEbiotech & ANRS\MIE: ANRS |MIE et France Biotech organisent les 1ères rencontres entre les acteurs de la #healthtech et les #chercheurs du réseau ANRS | MIE sur la...
As a member of the FunHoMic Network, BIOASTER invites you to join to the final FunHoMic’s conference on April 5 and 6, 2023 about “The Fungus-Host-Microbiota interplay” that will take...
BIOASTER is pleased to announce that the B2B2B AMR Dx consortium has officially been recommended for funding (B2B2B AMR Dx: Bench, Bedside, Business, and Beyond: innovative solutions for AMR diagnostics)...
ADOR Diagnostics, the international IVD company headquartered in Rome and BIOASTER, the French Microbiology Technology Research Institute, have today announced the beginning of a cooperation to develop molecular diagnostic tests...
PiLeJe Laboratoire and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights on the immunomodulatory potential of selected probiotics in the context of...
#PhageTherapy at BIOASTER At @Bioaster, we have developed #preclinicalModels allowing To follow the concentration of #phages over time (#pharmacokinetics) in different fluids and organs after administration by various routes On...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
